# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJ302-IM in Healthy Volunteers

> **NCT06625541** · PHASE1 · COMPLETED · sponsor: **AnnJi Pharmaceutical Co., Ltd.** · enrollment: 57 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** AJ302-IM
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06625541
- **Lead sponsor:** AnnJi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-24
- **Primary completion:** 2025-08-15
- **Final completion:** 2025-08-15
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06625541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06625541, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJ302-IM in Healthy Volunteers". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06625541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*